LONDON & EXTON, Pa.--(BUSINESS WIRE)--April 13, 2006--GlaxoSmithKline (NYSE:GSK - News) and Adolor Corporation (Nasdaq:ADLR - News) announced today that GSK has completed enrollment of the Phase 3 clinical program to evaluate the efficacy and safety of the oral investigational drug Entereg® (alvimopan) for the treatment of gastrointestinal adverse events caused by opioids used for persistent non-cancer pain. Enrollment of a Phase 2b study in cancer patients with persistent pain has also been completed.
